|
|
|
|
|
|
Sponsors and Collaborators: |
Schering-Plough AESCA Pharma GmbH |
Information provided by: | Schering-Plough |
ClinicalTrials.gov Identifier: | NCT00279565 |
This randomized, single-center, controlled study is designed to evaluate the safety, tolerability, and efficacy of treatment with Peg-Intron with Rebetol in methadone or buprenorphine maintenance patients with hepatitis C.
Condition | Intervention | Phase |
Hepatitis C, Chronic |
Drug: buprenorphine Drug: methadone Drug: pegylated interferon alfa-2b plus ribavirin |
Phase IV |
MedlinePlus related topics: | Hepatitis Hepatitis C |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Randomized, Controlled Study of Buprenorphine and Methadone in Hepatitis C Patients in Need of Treatment |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Lab parameters:
Exclusion Criteria:
Study ID Numbers: | P04279 |
First Received: | January 17, 2006 |
Last Updated: | February 28, 2007 |
ClinicalTrials.gov Identifier: | NCT00279565 |
Health Authority: | Austria: Federal Ministry for Health and Women |
|
|
|
|
|